Fiera Capital Corp Purchases 4,783 Shares of BeOne Medicines Ltd. – Sponsored ADR $ONC

Fiera Capital Corp lifted its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 19.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,900 shares of the company’s stock after purchasing an additional 4,783 shares during the quarter. Fiera Capital Corp’s holdings in BeOne Medicines were worth $9,084,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ONC. Leonteq Securities AG purchased a new stake in BeOne Medicines in the 4th quarter valued at about $35,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines in the 2nd quarter worth approximately $35,000. CWM LLC boosted its holdings in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the period. Farther Finance Advisors LLC boosted its holdings in BeOne Medicines by 21.8% in the 4th quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after buying an additional 39 shares during the period. Finally, EverSource Wealth Advisors LLC bought a new position in BeOne Medicines in the 2nd quarter worth approximately $68,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on ONC. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Truist Financial reissued a “buy” rating and issued a $413.00 price target (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Wolfe Research began coverage on shares of BeOne Medicines in a report on Friday, March 27th. They issued an “outperform” rating and a $340.00 price target for the company. Jefferies Financial Group downgraded shares of BeOne Medicines from a “buy” rating to a “hold” rating and cut their price target for the company from $420.00 to $290.00 in a report on Monday, March 16th. Finally, Barclays raised their price objective on shares of BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $390.00.

Insider Buying and Selling at BeOne Medicines

In related news, Director Margaret Dugan sold 212 shares of BeOne Medicines stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $309.60, for a total value of $65,635.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Chan Henry Lee sold 341 shares of BeOne Medicines stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $300.00, for a total transaction of $102,300.00. The SEC filing for this sale provides additional information. Insiders have sold 1,641 shares of company stock worth $505,791 in the last 90 days. 6.19% of the stock is owned by company insiders.

BeOne Medicines Stock Performance

BeOne Medicines stock opened at $270.80 on Tuesday. The firm’s fifty day moving average price is $301.74 and its 200-day moving average price is $316.81. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The stock has a market cap of $29.71 billion, a P/E ratio of 60.58 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $239.25 and a fifty-two week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. On average, equities research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.